Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,932 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the sale, the insider owned 29,190 shares of the company’s stock, valued at $790,757.10. This trade represents a 9.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $27.18 on Monday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -3.88 and a beta of 0.89. The business’s fifty day moving average price is $32.20 and its two-hundred day moving average price is $35.97.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business had revenue of $12.88 million for the quarter, compared to the consensus estimate of $10.49 million. During the same period in the prior year, the company posted $16.22 earnings per share. Agios Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $242,000. CANADA LIFE ASSURANCE Co grew its position in Agios Pharmaceuticals by 3.4% in the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 662 shares during the last quarter. TCG Crossover Management LLC raised its stake in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after acquiring an additional 733,038 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Agios Pharmaceuticals during the third quarter worth about $5,881,000. Finally, Voleon Capital Management LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth about $268,000.

Analysts Set New Price Targets

AGIO has been the topic of several recent research reports. JPMorgan Chase & Co. lowered their target price on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, November 21st. Truist Financial increased their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. The Goldman Sachs Group lowered their price objective on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, November 20th. Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.